130 related articles for article (PubMed ID: 32758705)
1. An input-controlled model system for identification of MHC bound peptides enabling laboratory comparisons of immunopeptidome experiments.
Klatt MG; Aretz ZEH; Curcio M; Gejman RS; Jones HF; Scheinberg DA
J Proteomics; 2020 Sep; 228():103921. PubMed ID: 32758705
[TBL] [Abstract][Full Text] [Related]
2. Improving MHC-I Ligand Identifications from LC-MS/MS Data by Incorporating Allelic Peptide Motifs.
Konda P; Murphy JP; Gujar S
Proteomics; 2019 Mar; 19(5):e1800458. PubMed ID: 30710433
[TBL] [Abstract][Full Text] [Related]
3. Critical Review of Existing MHC I Immunopeptidome Isolation Methods.
Kuznetsov A; Voronina A; Govorun V; Arapidi G
Molecules; 2020 Nov; 25(22):. PubMed ID: 33228004
[TBL] [Abstract][Full Text] [Related]
4. Protocol for purification and identification of MHC class I immunopeptidome from cancer cell lines.
Mohan SV; Datta KK; Ziegman R; Smith C; Gowda H
STAR Protoc; 2021 Mar; 2(1):100385. PubMed ID: 33778779
[TBL] [Abstract][Full Text] [Related]
5. Rapid and sensitive identification of major histocompatibility complex class I-associated tumor peptides by Nano-LC MALDI MS/MS.
Hofmann S; Glückmann M; Kausche S; Schmidt A; Corvey C; Lichtenfels R; Huber C; Albrecht C; Karas M; Herr W
Mol Cell Proteomics; 2005 Dec; 4(12):1888-97. PubMed ID: 16112985
[TBL] [Abstract][Full Text] [Related]
6. Mild Acid Elution and MHC Immunoaffinity Chromatography Reveal Similar Albeit Not Identical Profiles of the HLA Class I Immunopeptidome.
Sturm T; Sautter B; Wörner TP; Stevanović S; Rammensee HG; Planz O; Heck AJR; Aebersold R
J Proteome Res; 2021 Jan; 20(1):289-304. PubMed ID: 33141586
[TBL] [Abstract][Full Text] [Related]
7. Identification of Immunodominant HIV-1 Epitopes Presented by HLA-C*12:02, a Protective Allele, Using an Immunopeptidomics Approach.
Chikata T; Paes W; Akahoshi T; Partridge T; Murakoshi H; Gatanaga H; Ternette N; Oka S; Borrow P; Takiguchi M
J Virol; 2019 Sep; 93(17):. PubMed ID: 31217245
[TBL] [Abstract][Full Text] [Related]
8. Enhanced Mass Spectrometry Detection of MHC Peptides.
Chen R; Li J
Methods Mol Biol; 2019; 2024():245-257. PubMed ID: 31364054
[TBL] [Abstract][Full Text] [Related]
9. Solving an MHC allele-specific bias in the reported immunopeptidome.
Klatt MG; Mack KN; Bai Y; Aretz ZEH; Nathan LI; Mun SS; Dao T; Scheinberg DA
JCI Insight; 2020 Oct; 5(19):. PubMed ID: 32897882
[TBL] [Abstract][Full Text] [Related]
10. Predicted MHC peptide binding promiscuity explains MHC class I 'hotspots' of antigen presentation defined by mass spectrometry eluted ligand data.
Jappe EC; Kringelum J; Trolle T; Nielsen M
Immunology; 2018 Jul; 154(3):407-417. PubMed ID: 29446062
[TBL] [Abstract][Full Text] [Related]
11. Mass spectrometry-based identification of MHC-bound peptides for immunopeptidomics.
Purcell AW; Ramarathinam SH; Ternette N
Nat Protoc; 2019 Jun; 14(6):1687-1707. PubMed ID: 31092913
[TBL] [Abstract][Full Text] [Related]
12. The interdependence of machine learning and LC-MS approaches for an unbiased understanding of the cellular immunopeptidome.
Nielsen M; Ternette N; Barra C
Expert Rev Proteomics; 2022 Feb; 19(2):77-88. PubMed ID: 35390265
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive analysis of MHC ligands in clinical material by immunoaffinity-mass spectrometry.
Kasuga K
Methods Mol Biol; 2013; 1023():203-18. PubMed ID: 23765629
[TBL] [Abstract][Full Text] [Related]
14. Identification and Mitigation of Defensins in the Immunopurification of Peptide MHC-I Antigens from Lung Tissue.
Chow DT; Rardin MJ
J Am Soc Mass Spectrom; 2022 Sep; 33(9):1590-1597. PubMed ID: 34645265
[TBL] [Abstract][Full Text] [Related]
15. Mapping the tumour human leukocyte antigen (HLA) ligandome by mass spectrometry.
Freudenmann LK; Marcu A; Stevanović S
Immunology; 2018 Jul; 154(3):331-345. PubMed ID: 29658117
[TBL] [Abstract][Full Text] [Related]
16. In-depth mining of the immunopeptidome of an acute myeloid leukemia cell line using complementary ligand enrichment and data acquisition strategies.
Pandey K; Mifsud NA; Lim Kam Sian TCC; Ayala R; Ternette N; Ramarathinam SH; Purcell AW
Mol Immunol; 2020 Jul; 123():7-17. PubMed ID: 32387766
[TBL] [Abstract][Full Text] [Related]
17. PeptiCHIP: A Microfluidic Platform for Tumor Antigen Landscape Identification.
Feola S; Haapala M; Peltonen K; Capasso C; Martins B; Antignani G; Federico A; Pietiäinen V; Chiaro J; Feodoroff M; Russo S; Rannikko A; Fusciello M; Koskela S; Partanen J; Hamdan F; Tähkä SM; Ylösmäki E; Greco D; Grönholm M; Kekarainen T; Eshaghi M; Gurvich OL; Ylä-Herttuala S; M Branca RM; Lehtiö J; Sikanen TM; Cerullo V
ACS Nano; 2021 Oct; 15(10):15992-16010. PubMed ID: 34605646
[TBL] [Abstract][Full Text] [Related]
18. Neoantigen characteristics in the context of the complete predicted MHC class I self-immunopeptidome.
Brown SD; Holt RA
Oncoimmunology; 2019; 8(3):1556080. PubMed ID: 30723589
[TBL] [Abstract][Full Text] [Related]
19. Accurate quantitation of MHC-bound peptides by application of isotopically labeled peptide MHC complexes.
Hassan C; Kester MG; Oudgenoeg G; de Ru AH; Janssen GM; Drijfhout JW; Spaapen RM; Jiménez CR; Heemskerk MH; Falkenburg JH; van Veelen PA
J Proteomics; 2014 Sep; 109():240-4. PubMed ID: 25050860
[TBL] [Abstract][Full Text] [Related]
20. Digging deeper into the immunopeptidome: characterization of post-translationally modified peptides presented by MHC I.
Mangalaparthi KK; Madugundu AK; Ryan ZC; Garapati K; Peterson JA; Dey G; Prakash A; Pandey A
J Proteins Proteom; 2021; 12(3):151-160. PubMed ID: 36619276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
